title: Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles.
abstract: During myocardial infarction (MI), high levels of circulating procoagulant microparticles (MP) shed from endothelial cells and platelets diffuse prothrombotic and proinflammatory potentials crucial for the coronary prognosis. In addition to conventional treatments, we evaluated whether vitamin C treatment could modify circulating levels of procoagulant MP. Upon admission, 61 patients with MI were prospectively randomized for immediate additional vitamin C treatment. Circulating MP were quantified by functional prothrombinase assay before and after 5 days of vitamin C administration (1 g day-1). The cellular origin of MP was also assessed. In vitamin C-treated patients, the reduction in platelet-derived MP was 10% higher (P = 0.01). In patients with diabetes mellitus, dyslipidemia or more than two cardiovascular risk factors, vitamin C decreased endothelial and platelet-derived MP levels by approximately 70% and 13%, respectively. This early effect on circulating platelet and endothelial-derived MP, testifies to the importance of oxidative stress during MI. Vitamin C could prove beneficial for the outcome of patients at higher thrombotic risk.
authors.affiliation: Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, France.
authors.forename: O
authors.initials: O
authors.lastname: Morel
authors.forename: L
authors.initials: L
authors.lastname: Jesel
authors.forename: B
authors.initials: B
authors.lastname: Hugel
authors.forename: M-P
authors.initials: MP
authors.lastname: Douchet
authors.forename: M
authors.initials: M
authors.lastname: Zupan
authors.forename: M
authors.initials: M
authors.lastname: Chauvin
authors.forename: J-M
authors.initials: JM
authors.lastname: Freyssinet
authors.forename: F
authors.initials: F
authors.lastname: Toti
mesh_terms: D000208:Acute Disease; D000368:Aged; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001792:Blood Platelets / Q000378:metabolism; D002316:Cardiotonic Agents / Q000627:therapeutic use; D017023:Coronary Angiography; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D015539:Platelet Activation / Q000187:drug effects* / Q000502:physiology; D011446:Prospective Studies; D012307:Risk Factors; D013925:Thromboplastin / Q000378:metabolism
chemical_list: D002316:Cardiotonic Agents; D013925:Thromboplastin; D001205:Ascorbic Acid